Skip to main content
Premium Trial:

Request an Annual Quote

PPD Discovery to License Affymetrix Chips and Software

NEW YORK, Jan 31 - PPD Discovery said Wednesday it would license Affymetrix' GeneChip DNA microarrays as well as its array instrumentation and analysis software.

The company will use the Affymetrix products in its functional genomics-based drug target validation efforts. PPD Discovery, a subsidiary of drug discovery and development services company PPD, uses its genomics platform to isolate gene inhibitors for cells, in order to identify novel therapeutic targets and gain insights on genome function.

" Affymetrix' technology adds a new dimension to our functional genomics program,"  Tanya Holzmayer, vice president of genomics at PPD Discovery, said in a statement. " We have evaluated a variety of expression profiling technologies and believe that Affymetrix' GeneChip technology will considerably expedite our process of target validation."

The companies did not disclose the financial terms of the agreement.

Some of Affymetrix’s other GeneChip Platform and service access customers have included Astra, Bristol-Myers Squibb, DNAX, Eli Lilly, Human Genome Sciences, Genecor, Glaxo Wellcome, Merck, Millennium, Novartis, Pharmacia & Upjohn, Pioneer, Research Genetics, Rosetta, Sanofi Recherche, Schering, and Tularik.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.